Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 5/2017

25.09.2017 | Myeloproliferative Neoplasms (B Stein, Section Editor)

Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature

verfasst von: Amy Zhou, Amber Afzal, Stephen T. Oh

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The prognosis for patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs) is highly variable. All Ph-negative MPNs carry an increased risk for thrombotic complications, bleeding, and leukemic transformation. Several clinical, biological, and molecular prognostic factors have been identified in recent years, which provide important information in guiding management of patients with Ph-negative MPNs. In this review, we critically evaluate the recent published literature and discuss important new developments in clinical and molecular factors that impact survival, disease transformation, and thrombosis in patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Recent Findings

Recent studies have identified several clinical factors and non-driver mutations to have prognostic impact on Ph-negative MPNs independent of conventional risk stratification and prognostic models. In polycythemia vera (PV), leukocytosis, abnormal karyotype, phlebotomy requirement on hydroxyurea, increased bone marrow fibrosis, and mutations in ASXL1, SRSF2, and IDH2 were identified as additional adverse prognostic factors. In essential thrombocythemia (ET), JAK2 V617F mutation, splenomegaly, and mutations in SH2B3, SF3B1, U2AF1, TP53, IDH2, and EZH2 were found to be additional negative prognostic factors. Bone marrow fibrosis and mutations in ASXL1, SRSF2, EZH2, and IDH1/2 have been found to be additional prognostic factors in primary myelofibrosis (PMF). CALR mutations appear to be a favorable prognostic factor in PMF, which has not been clearly demonstrated in ET.

Summary

The prognosis for patients with PV, ET, and PMF is dependent upon the presence or absence of several clinical, biological, and molecular risk factors. The significance of additional risk factors identified in these recent studies will need further validation in prospective studies to determine how they may be best utilized in the management of these disorders.
Literatur
1.
Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.CrossRefPubMed
2.
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573–82.CrossRefPubMed
3.
•• Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405. This paper provides one of the first descriptions of mutations in CALR in ET and PMF. CrossRefPubMedPubMedCentral
4.
•• Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. This paper provides one of the first descriptions of mutations in CALR in ET and PMF and suggests a more favorable prognosis for patients with CALR mutations. CrossRefPubMed
5.
Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.CrossRefPubMed
6.
Boyd EM, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol. 2010;149(2):250–7.CrossRefPubMed
7.
Pardanani A, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25(12):1834–9.CrossRefPubMed
8.
Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.CrossRefPubMed
9.
Noor SJ, et al. Myeloid blastic transformation of myeloproliferative neoplasms—a review of 112 cases. Leuk Res. 2011;35(5):608–13.CrossRefPubMed
10.
Bjorkholm M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410–5.CrossRefPubMedPubMedCentral
11.
• Tefferi A, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13. quiz 2615. This paper is one of the largest cohort studies examining the prognostic impact of driver mutations (JAK2/CALR/MPL) on survival in ET, PV, and PMF. CrossRefPubMedPubMedCentral
12.
Hultcrantz M, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995–3001.CrossRefPubMedPubMedCentral
13.
Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–901.CrossRefPubMed
14.
Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.CrossRefPubMed
15.
Gangat N, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7.CrossRefPubMed
16.
Barbui T, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–33.CrossRefPubMed
17.
Barbui T, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.CrossRefPubMedPubMedCentral
18.
Ospedali R, Barbui T, Finazzi G, de Gaetano G, Marchioli R, Tognoni G, et al. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656–64.
19.
Marchioli R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.CrossRefPubMed
20.
Gangat N, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354–8.CrossRefPubMed
21.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(1):94–108.CrossRefPubMed
22.
•• Tefferi A, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81. This paper is one of the largest cohort studies on the outcome of patients with PV and the clinical prognostic factors that impact survival. CrossRefPubMedPubMedCentral
23.
Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.CrossRefPubMed
24.
Marchioli R, et al. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.CrossRefPubMedPubMedCentral
25.
Alvarez-Larran A, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017;102(1):103–9.CrossRefPubMedPubMedCentral
26.
Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(17):1670–1.CrossRefPubMed
27.
Verstovsek S, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821–9.CrossRefPubMedPubMedCentral
28.
Abdulkarim K, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148–55.CrossRefPubMed
29.
Kreft A, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113(2):137–43.CrossRefPubMed
30.
Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders—aids to diagnosis and classification. Ann Hematol. 1999;78(11):495–506.CrossRefPubMed
31.
Barbui T, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239–41.CrossRefPubMed
32.
Barraco D, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538.CrossRefPubMedPubMedCentral
33.
34.
Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668–76.CrossRefPubMed
35.
Passamonti F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813–6.CrossRefPubMed
36.
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–79.CrossRefPubMed
37.
•• Tefferi A, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances. 2016;1(1):21–30. This paper provides one of the first descriptions of the frequency of non-driver mutations in PV and ET and their prognostic impact. CrossRef
38.
• Guglielmelli P, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804–10. This paper is one of the first to demonstrate that the number of adverse non-driver mutations impacts survival in PMF. CrossRefPubMed
39.
Passamonti F, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–61.CrossRefPubMed
40.
Barbui T, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179–84.CrossRefPubMed
41.
Gangat N, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270–6.CrossRefPubMed
42.
Passamonti F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197–201.CrossRefPubMed
43.
Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–92.CrossRefPubMedPubMedCentral
44.
Haider M, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91(4):390–4.CrossRefPubMed
45.
Kittur J, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109(11):2279–84.CrossRefPubMed
46.
Campbell PJ, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945–53.CrossRefPubMed
47.
Picardi M, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood. 2002;99(11):4228–30.CrossRefPubMed
48.
Andriani A, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1297 patients. Am J Hematol. 2016;91(3):318–21.CrossRefPubMed
49.
Barbui T, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569–71.CrossRefPubMed
50.
Haider M, et al. Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. Am J Hematol. 2016;91(5):E296–7.CrossRefPubMed
51.
• Tefferi A, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28(12):2300–3. This paper was one of the first studies to evaluate the impact of CALR mutations on survival in a large ET cohort. CrossRefPubMed
52.
•• Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861–9. This paper is one of the first to evaluate the impact of non-driver mutations in PMF and identified ASXL1, SRSF2, EZH2, and IDH1/2 as adverse prognostic factors associated with decreased survival and increased leukemic transformation. CrossRefPubMed
53.
Visconte V, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26(3):542–5.CrossRefPubMed
54.
Broseus J, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036–41.CrossRefPubMedPubMedCentral
55.
Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905–14.CrossRefPubMed
56.
Mesa RA, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973–7.CrossRefPubMed
57.
Zhou A, Oh ST. Prognostication in MF: from CBC to cytogenetics to molecular markers. Best Pract Res Clin Haematol. 2014;27(2):155–64.CrossRefPubMed
58.
Caramazza D, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82–8.CrossRefPubMed
59.
Patnaik MM, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84(2):105–8.CrossRefPubMed
60.
Guglielmelli P, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918–22.CrossRefPubMed
61.
Guglielmelli P, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227–34.CrossRefPubMed
62.
Li B, et al. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. Blood Cancer J. 2016;6(12):e505.CrossRefPubMedPubMedCentral
63.
Barosi G, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030–6.CrossRefPubMed
64.
Campbell PJ, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107(5):2098–100.CrossRefPubMed
65.
Tefferi A, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756–61.CrossRefPubMed
66.
Guglielmelli P, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477–83.CrossRefPubMed
67.
Guglielmelli P, et al. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94(1):144–6.CrossRefPubMed
68.
• Tefferi A, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472–7. This study was one of the first to evaluate the prognostic impact of JAK2/CALR/MPL mutations on a large PMF cohort. CrossRefPubMed
69.
Pei YQ, et al. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol. 2016;95(9):1391–8.CrossRefPubMed
70.
• Tefferi A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124(15):2465–6. This paper is one of the first to report on a difference in prognostic impact between type-1 and type-2 CALR mutations. CrossRefPubMedPubMedCentral
71.
• Rumi E, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–9. This study was one of the first to evaluate the prognostic impact of JAK2/CALR/MPL mutations on survival in a large PMF cohort. CrossRefPubMedPubMedCentral
72.
Li B, et al. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. Am J Hematol. 2016;91(7):E320–1.CrossRefPubMed
73.
74.
Pietra D, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–8.CrossRefPubMed
75.
•• Marty C, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317–24. This paper was one of the first to demonstrate the effect of CALR mutations in mice and the difference in phenotype generated by type-1 and type-2 mutations. CrossRefPubMed
76.
Tefferi A, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431–3.CrossRefPubMed
77.
Barraco D, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6:e416.CrossRefPubMedPubMedCentral
Metadaten
Titel
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature
verfasst von
Amy Zhou
Amber Afzal
Stephen T. Oh
Publikationsdatum
25.09.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 5/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0401-2

Weitere Artikel der Ausgabe 5/2017

Current Hematologic Malignancy Reports 5/2017 Zur Ausgabe

Myeloproliferative Neoplasms (B Stein, Section Editor)

Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

Myeloproliferative Neoplasms (B Stein, Section Editor)

Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis

Myelodysplastic Syndromes (M Savona, Section Editor)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes

Myelodysplastic Syndromes (M Savona, Section Editor)

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

Myeloproliferative Neoplasms (B Stein, Section Editor)

Familial MPN Predisposition

Myelodysplastic Syndromes (M Savona, Section Editor)

Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise